Search
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Teprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigational[L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was … approved by the FDA in January 2020 for the treatment of TED.
Synonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimerMegestrol acetate
go.drugbank.com/drugs/DB00351ApprovedInvestigationalVet approvedAs the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Products: Megex-I Suspension 800mg/20mlTemafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnIt was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three … Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class.
Categories: Topoisomerase II InhibitorsEverolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIn a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. … It is currently used as an immunosuppressant to prevent rejection of organ transplants.
Vilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support … The drug is not yet fully approved for this condition.[L45849]
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalFondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in … patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable
Zucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions.
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing
Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigationalLumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.